The CDC is investigating the death of an Oregon woman who developed a rare blood clot after receiving Johnson & Johnson’s vaccine

  • The CDC is investigating the death of an Oregon woman who not too long ago obtained the J&J vaccine.

  • The woman developed a rare blood clot inside two weeks of getting her shot.

  • For now, there isn’t any definitive hyperlink between her death and the vaccine.

  • See more stories on Insider’s business page.

The Centers for Disease Control and Prevention is investigating the death of an Oregon woman who developed a rare, however severe blood clot inside two weeks of receiving Johnson & Johnson’s vaccine, the Oregon Health Authority (OHA) introduced Thursday.

The woman, who was in her 50s, obtained her shot earlier than US regulators paused the distribution of J&J’s vaccine final week.

The pause adopted six studies of central venous sinus thrombosis (CVST), a rare blood clot that kinds in the mind, amongst girls ages 18 and 48 who had obtained J&J’s shot. The girls equally developed the clots inside two weeks of being vaccinated. They additionally reported low ranges of platelets – colorless blood cells that assist clots kind.

In a assertion, the OHA mentioned the Oregon woman had the identical mixture of a rare blood clot and low platelets.

Dr. Shimi Sharief, senior well being advisor with the OHA, informed reporters that the woman’s signs had been in step with that of the different blood clot circumstances. Symptoms for this sort of clot embrace extreme and weird headache, shortness of breath, stroke-like signs, stomach ache, and small microbleeds.

Sharief emphasised that the potential adversarial response is very rare.

More than eight million doses of J&J’s vaccine have been administered in the US – so circumstances of CVST following the shot are nonetheless fewer than one in a million. In an common 12 months, CVST happens in about 5 individuals out of each million.

Dr. Janet Woodcock, the Food and Drug Administration’s appearing commissioner, told The New York Times that US regulators had recognized extra blood clot circumstances since the authentic six had been reported, however the quantity – which she didn’t present – wasn’t an “avalanche” or “big surge.”

The CDC will resolve whether or not to renew J&J vaccinations on Friday

johnson & johnson vaccine

Nurse Elizabeth Johnson administers a COVID-19 vaccine to Melissa Mendez in Reading, Pennsylvania. Ben Hasty/MediaNews Group/Reading Eagle/Getty Images

The CDC is nonetheless investigating whether or not the CVST circumstances are associated to the J&J vaccine. On Friday, an independent advisory panel for the CDC will vote on whether or not to finish the pause on the shot – 10 days after the advice was issued.

The death of the Oregon woman shall be mentioned at that assembly. The woman is the second death related to rare blood clots following the J&J vaccine: A 45-year-old woman in Virginia additionally died after receiving the shot in March.

Sharief mentioned that, to her information, Oregon well being authorities usually are not investigating another blood clot circumstances in the state.

Insider not too long ago spoke with five of the 15 CDC vaccine advisory committee members who are meeting on Friday. Barring any extra main surprises in the knowledge, all of them appeared desperate to get the vaccine again into syringes and arms throughout the nation.

“I’m not willing and eager to continue the pause for much further,” Dr. Wilbur Chen, a professor at the University of Maryland School of Medicine, informed Insider. “The truth is that the value of the vaccine is proven. 100% efficacy against hospitalization and death is virtually what the data is showing, so that’s terrific. And on the other side for the safety, we think that this [clotting] is super rare.”

He added: “For women 18 to 48 years, or 18 to 50 maybe, we may say ‘you may get vaccinated, but we’d like to just make sure that you are aware of this very rare event.'”

Read the authentic article on Business Insider

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *